TSILab - Homepage
Principal Investigators
Sonja Schrepfer, MD, PhD
Professor of Surgery, UCSF
Division of Cardiothoracic Surgery
Director, TSI Lab
Tobias Deuse, MD
Professor of Surgery, UCSF
Division of Cardiothoracic Surgery
The Julien I.E. Hoffman, M.D. Endowed Chair in Cardiac Surgery
Director, Minimally-invasive Cardiac Surgery
Surgical Director, Transcatheter Valve Program
Principal Investigator, TSI lab
Stem Cell & Transplant Immunobiology, Cardiovascular Disease, Space Medicine
The Transplant and Stem Cell Immunobiology (TSI) Laboratory uses multiple research directions to answer complex questions about stem cell therapy, heart and lung transplantation, and cardiovascular disease. Our laboratory focuses on the immunogenicity of allogeneic stem cells, tissues, and organs, and is interested in designing methods to prevent immunological recognition and rejection of such materials.
We are also interested in better understanding and preventing mechanisms that result in cardiovascular disease. With topics that range from basic science (e.g. identifying novel molecules involved in pluripotent stem cell immunogenicity) to translational medicine (e.g. developing drugs that may be useful in reducing myointimal hyperplasia), we take a wide-angle approach to our research.
Currently, we are involved in exciting cardiovascular research funded by the National Aeronautics and Space Administration (NASA). In addition to our excellent team at UCSF, we also work closely both scientifically and collaboratively with our sister laboratory in Hamburg, Germany.
Featured Publications
- Hu X, White K, Olroyd AG, DeJesus R, Dominguez A, Dowdle WE, Friera AM, Young A, Wells F, Chu EY, McGill TJ, Lin A, Egenberger K, Gagnon A, Rukstalis JM, Hogrebe NJ, Gattis C, Basco R, Millman JR, Kievit P, Davis MM, Lanier LL, Connolly AJ, Deuse T, Schrepfer S. Hypoimmune rhesus macaque induced pluripotent stem cells achieve long-term survival in fully immunocompetent allogeneic recipients. Nat Biotechnol. 2023; doi: 10.1038/s41587-023-01784-x.
- Hu X, Gattis C, Olroyd AG, Friera AM, White K, Young C, Basco R, Lamba M, Wells F, Ankala R, Dowdle WE, Lin A, Egenberger K, Rukstalis JM, Millman JR, Connolly AJ, Deuse T, Schrepfer S. Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice. Sci Transl Med. 2023 Apr 12;15(691):eadg5794. doi: 10.1126/scitranslmed.adg5794.
- Hu X, Manner K, DeJesus R, White K, Gattis C, Ngo P, Bandoro C, Tham E, Chu EY, Young C, Wells F, Basco R, Friera A, Kangeyan D, Beauchesne P, Dowdle WE, Deuse T, Fry TJ, Foster AE, Schrepfer S. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice. Nat Commun. 2023 Apr 10;14(1):2020. doi: 10.1038/s41467-023-37785-2.
- Gravina A, Tediashvili G, Rajalingam R, Quandt Z, Deisenroth C, Schrepfer S, Deuse T. CD64 expression protects cell therapeutics from antibody-mediated rejection. Nat Biotechnol 2023 Jan 2. doi: 10.1038/s41587-022-01540-7.
- Deuse T, Tediashvili G, Hu X, Gravina A, Tamenang A, Wang D, Connolly A, Mueller C, Mallavia B, Looney MR, Alawi A, Lanier LL, Schrepfer S. Hypoimmune iPSC-derived cell products treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice. PNAS 2021;118(28):e2022091118.
- Deuse T, Hu X, Agbor-Enoh S, Jang MK, Alawi M, Saygi C, Gravina A, Tediashvili G, Nguyen VQ, Liu Y, Valantine H, Lanier LL, Schrepfer S. The SIRPα-CD47 immune checkpoint in NK cells. J Exp Med. 2021;218(3):e20200839.
- Deuse T, Hu X, Gravina A, Wang D, Tediashvili G, De C, WO. T, Wahl A, Garcia J, Davis MM, Lanier LL, Schrepfer S. Hypo-immunogenic iPSC-derivatives show long-term survival in fully immunocompetent allogeneic recipients. Nat Biotechnol. 2019;37(3):252-258. doi: 10.1038/s41587-019-0016-3.